ERBB2 and breast cancer: Multivariate analysis demonstrated that RCB-TILs (+) served as an independent factor impacting recurrence following NAC across all BC patients (hazard ratio [HR] = 0.225, 95% confidence interval [CI]: 0.099 – 0.508, P < 0.001), including hormone receptor-positive patients (HR = 0.213, 95%CI: 0.067 – 0.682, P = 0.009), HER2-positive patients (HR = 0.216, 95%CI: 0.048 – 0.968, P = 0.045), and those with triple-negative BC (HR = 0.220, 95%CI: 0.049 – 0.989, P = 0.048).